Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program

Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first ...
Business Wire

Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus

The Company announced the development of the first antiviral to combat BK virus, one of the most common viral infections in transplant patients CANTON, Mass.--(BUSINESS WIRE)--Orthogon Therapeutics ...
VentureBeat

Orthogon Therapeutics Closes Oversubscribed $5.2M Financing to Advance First Oral Therapy for BK Polyomavirus

Orthogon’s small molecule therapeutics redefine treatment possibilities for BK virus infections. CANTON, Mass.–(BUSINESS WIRE)–December 10, 2024– Orthogon Therapeutics, a developer of novel antiviral ...
Seeking Alpha

Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of ...

Presenter: Jonathan Barratt, Ph.D., FRCP, The Mayer Professor of Renal Medicine, University of Leicester, U.K. About MAU868 MAU868, a first-in-class monoclonal antibody, has the potential to ...
Yahoo

Widespread cold virus you've never heard of may play key role in bladder cancer

When you buy through links on our articles, Future and its syndication partners may earn a commission. The BK virus, caught by most people in childhood, typically causes symptoms of the common cold.